Top Markets
#1 Threshold Network Threshold Network +62.80%
#2 TENDIES TENDIES +61.17%
#3 Cash Cat Cash Cat +21.87%
#4 OSK OSK +15.93%
#5 Magma Finance Magma Finance +14.69%
#6 Falcon Finance Falcon Finance +13.21%
#7 Kite Kite +12.89%
#8 Ape and Pepe Ape and Pepe +12.62%
#9 Asteroid Shiba Asteroid Shiba +11.93%
#10 SkyAI SkyAI +8.40%
Coin of the day
Threshold Network Threshold Network
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Cellectis S.A. Cellectis S.A.

Cellectis S.A.

ALCLS
Classement en actions #17125
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Prix de l'action
$3.56
Capitalisation boursière
$257.37M
Changement (1 jour)
5.26%
Changement (1 an)
38.35%
Pays
FR
Échange Cellectis S.A. (ALCLS)

Catégorie

Healthcare
Historique du prix de l'action pour Cellectis S.A. (ALCLS)
Prix de clôture le plus élevé : $3.46 le 2026-09-01

Prix de clôture le plus bas : $17.72 le 2007-02-01
Historique du prix de l'action de Cellectis S.A. de 2007 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) -20.49%
2025 169.48%
2024 -42.86%
2023 40.69%
2022 -74.52%
2021 -70.75%
2020 74.88%
2019 -10.96%
2018 -29.07%
2017 53.46%
2016 -41.97%
2015 106.63%
2014 307.22%
2013 -61.60%
2012 7.76%
2011 -4.53%
2010 -42.92%
2009 103.43%
2008 -44.49%
2007 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.15 36.70%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 45.33%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $153.87 536.09%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.21 -10.03%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $757.71 8.20%
CH